Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. scores highest on Nitro (54) and lowest on Price (21). Its PosiPenta is 35.04 out of 100, weaker than most similar companies.
On the Penta Grid this week, Enanta Pharmaceuticals, Inc. is Grid #668 of 837 in the Healthcare sector in United States, and Grid #3,294 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. | 35.04 | 21 | 26 | 54 | 25 | 50 |
| Zura Bio Limited | 52.38 | 30 | 47 | 47 | 68 | 69 |
| Scribe Therapeutics Inc. | 45.15 | 0 | 22 | 51 | 93 | 59 |
| Galectin Therapeutics Inc. | 50.76 | 0 | 33 | 54 | 96 | 71 |
| Nautilus Biotechnology, Inc. | 46.30 | 29 | 37 | 53 | 49 | 63 |
| Alpha Teknova, Inc. | 50.71 | 11 | 58 | 80 | 48 | 56 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.59 |
| P/B ratio | 3.20 |
EEarnings
| Trailing EPS | ₹-229.21 |
| Forward EPS | ₹-224.85 |
NNitro
| Price | 1051.34 |
| 52-week high | 1624.36 |
| 52-week low | 966.09 |
| Fall from 52-week high | 35.3% |
TTorque
| Return on equity (ROE) | -70.12% |
| Debt-to-equity | 1.80 |
AAnchor
| Beta (price swings) | 0.96 |
| Market cap | ₹3,062 Cr |
| Insider holding | 4.67% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Enanta Pharmaceuticals, Inc.'s PosiPenta score?
Enanta Pharmaceuticals, Inc.'s PosiPenta is 35.04 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Enanta Pharmaceuticals, Inc. stand on the Penta Grid?
On the Penta Grid this week, Enanta Pharmaceuticals, Inc. is Grid #668 of 837 in the Healthcare sector in United States, and Grid #3,294 of 4,000 in United States.
Which PosiPenta pillar is strongest for Enanta Pharmaceuticals, Inc.?
Nitro (momentum), with a score of 54 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Enanta Pharmaceuticals, Inc.?
Price (valuation), with a score of 21 out of 100: weaker than most similar companies.
Has Enanta Pharmaceuticals, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.76 points, from 31.28 to 35.04.
PositoAI is for research and education only and is not investment advice.